Cobra Biologics Ltd.

49 articles with Cobra Biologics Ltd.

• 

  BioSpace Global Roundup, Aug. 20

  8/20/2020

  Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
• 

  BioSpace Global Roundup, July 16

  7/16/2020

  Biopharma and life sciences companies from across the globe provide updates on their business and pipelines.

• Cobra Biologics delivers final plasmids for production of CG01 in CombiGene's epilepsy project

  7/13/2020

  Further milestone paves the way for production of novel gene therapy drug candidate designed to treat drug-resistant focal epilepsy

• 

  Biopharma Update on the Novel Coronavirus: June 17

  6/17/2020

  Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 17, 2020.

• Cobra Biologics signs supply agreement with AstraZeneca for manufacture of COVID-19 vaccine candidate

  6/16/2020

   Cobra Biologics (Cobra), part of the Cognate BioServices family, an international CDMO for biologics and pharmaceuticals, today announced it has signed a supply agreement with AstraZeneca UK Ltd. ("AstraZeneca") to provide GMP manufacture of th

• Cobra Biologics is proud to be part of a consortium to rapidly develop a COVID-19 vaccine

  3/31/2020

  Keele, UK, 31 March 2020: Cobra Biologics, an international CDMO for biologics and pharmaceuticals, announced it is working as part of a consortium led by the Jenner Institute, Oxford University to rapidly develop, scale-up and produce the potential adenoviral vaccine candidate, ChAdOx1 nCov-19, for fast-tracked clinical trials for COVID-19.

• 

  Cobra Bio Secures $3.3 Million to Develop DNA Vaccine Against COVID-19

  3/30/2020

  Cobra Biologics and the Karolinska Institutet, secured millions in emergency funding from Horizon 2020 to support research and development and an eventual Phase I clinical trial testing of a DNA vaccine against COVID-19.

• Cognate BioServices closes Series B and completes acquisition of Cobra Biologics

  1/21/2020

  Cognate BioServices, a leading contract development and manufacturing organization specialized in cell and cell-mediated gene therapy products announced that it has completed the acquisition of Cobra Biologics, a leading CDMO specialized in providing development and manufacturing services for plasmid DNA and viral vector.

• 

  BioSpace Global Roundup, Nov. 7

  11/7/2019

  Biotech and pharmaceutical companies from across the globe provide updates on their business and pipelines.

• Cognate BioServices announces acquisition of Cobra Biologics

  11/4/2019

  Transformative acquisition creates global cell and gene therapy manufacturing services platform for both clinical and commercial products

• CombiGene signs agreement with Cobra Biologics for production of candidate drug CG01

  10/14/2019

  Collaboration supports progression of Epilepsy Gene Therapy toward clinical trials

• 

  BioSpace Global Roundup: June 27

  6/27/2019

  Biotech and pharma companies from across the globe share pipeline and business updates.

• Cobra Biologics and Symbiosis Complete £4.8m Viral Vector Supply Chain Collaboration

  6/25/2019

  Cobra Biologics (Cobra), an international contract development and manufacturing organisation (CDMO) focused on viral vector drug substance production, and Symbiosis Pharmaceutical Services (Symbiosis), a contract manufacturing organisation (CMO) specialising in the sterile manufacture of injectable viral vector drug products, today announced the successful completion of their collaboration to develop synergistic and world leading capabilities.

• 

  BioSpace Movers and Shakers: Jan. 18

  1/18/2019

  Pharma and biotech companies make changes to their board and leadership teams to advance pipelines and strategies, at SQZ, AstraZeneca, Bioasis, and more.

• Cobra Biologics appoints Dr Darrell Sleep as Director of Innovation

  1/15/2019

  Cobra Biologics (Cobra), an international CDMO for biologics and pharmaceuticals, today announced the appointment of Dr Darrell Sleep as Director of Innovation.

• Cobra Biologics, Pall Corporation and the Cell and Gene Therapy Catapult Win £1.5M Innovate UK Grant to Investigate Continuous Manufacturing for Gene Therapies

  11/26/2018

  Cobra Biologics has won a £1.5M shared grant from Innovate UK, the United Kingdom's innovation agency.

• Cobra Biologics and the University of Leeds Collaborate in BioProNET Funded Project

  10/30/2018

  £100K grant will fund proof-of-concept studies to optimise bioprocessing of gene therapy vectors using hydrodynamic fluid flow fields

• Cobra Biologics, GE Healthcare and Centre for Process Innovation Collaborate to Advance Gene Therapy

  9/25/2018

  Innovate UK funded project supports development of scalable, cost effective production of regenerative medicines

• Cobra Biologics and Symbiosis Awarded £1.9m ($2.5m USD) Innovate UK Grant

  2/7/2018

  The grant will position the partner companies as globally recognised centres of excellence in the field and firmly establish commercial viral vector manufacturing capabilities within the UK.

• Cobra Biologics Awarded $3.4M From Innovate UK

  1/23/2018

  The extended capacity and capability will allow Cobra increased process development, analytics and GMP manufacturing.